1. Show article details.

    BRIEF-Hercules Capital Announces The Appointment Of MS. Pam Randhawa To Its Board Of Directors

    Reuters – 7:44 AM ET 10/20/2021

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL ANNOUNCES THE APPOINTMENT OF MS. PAM RANDHAWA TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

  2. Show article details.

    Hercules Capital Announces the Appointment of Ms. Pam Randhawa to Its Board of Directors

    Business Wire – 6:00 AM ET 10/20/2021

    Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021.

  3. Show article details.

    BRIEF-Locus Biosciences Secures Financing Of Up To $25 Mln From Hercules Capital

    Reuters – 8:09 AM ET 10/19/2021

    Hercules Capital Inc (HTGC): * LOCUS BIOSCIENCES SECURES FINANCING OF UP TO $25 MILLION FROM HERCULES CAPITAL Source text for Eikon: Further company coverage:

  4. Show article details.

    Locus Biosciences Secures Financing of up to $25 Million from Hercules Capital

    GlobeNewswire – 7:30 AM ET 10/19/2021

    Locus Biosciences, Inc., a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial and inflammatory diseases, today announced that the company has entered a credit facility of up to $25 million with Hercules Capital, Inc. (HTGC), a specialty financing lender for life science and technology companies.

  5. Show article details.

    BRIEF-Axsome Therapeutics Expands Term Loan Facility With Hercules Capital To $300 Mln

    Reuters – 10:11 AM ET 10/18/2021

    Axsome Therapeutics Inc (AXSM): * AXSOME THERAPEUTICS EXPANDS TERM LOAN FACILITY WITH HERCULES CAPITAL TO $300 MILLION. * Axsome Therapeutics Inc (AXSM) - $100 MILLION NOW AVAILABLE UPON POTENTIAL FDA APPROVAL OF AXS-05. * AXSOME THERAPEUTICS (AXSM) - AMENDMENT EXTENDS MATURITY DATE OF FACILITY FROM ORIGINAL OCT 2025 TO OCT 2026, AND OPTIONALLY TO OCT 2027 Source text for Eikon: Further company coverage:

  6. Show article details.

    Hercules Capital Announces Date for Release of Third Quarter 2021 Financial Results and Conference Call

    Business Wire – 6:00 AM ET 10/14/2021

    Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2021 financial results conference call for Thursday, October 28, 2021, at 2:00 p.m. PT.

  7. Show article details.

    BRIEF-Eloxx Pharmaceuticals Secures Debt Facility Of Up To $30 Million From Hercules Capital

    Reuters – 8:10 AM ET 10/05/2021

    Eloxx Pharmaceuticals Inc (ELOX): * ELOXX PHARMACEUTICALS SECURES DEBT FACILITY OF UP TO $30 MILLION FROM HERCULES CAPITAL Source text for Eikon: Further company coverage:

  8. Show article details.

    Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

    GlobeNewswire – 8:00 AM ET 10/05/2021

    Eloxx Pharmaceuticals, Inc. (ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (HTGC), a specialty financing lender for life science and technology companies.

  9. Show article details.

    BRIEF-Corium Secures $235 Mln In Debt Financing

    Reuters – 8:25 AM ET 09/27/2021

    Hercules Capital Inc (HTGC): * CORIUM SECURES $235 MILLION IN DEBT FINANCING. * Hercules Capital Inc (HTGC) - PROCEEDS TO BE USED TO COMMERCIALIZE AZSTARYS AND ADVANCE PIPELINE. * HERCULES CAPITAL (HTGC) - CORIUM WILL RECEIVE AN INITIAL TRANCHE OF $100 MILLION, AND REMAINING FUNDS WILL BE AVAILABLE IN THREE ADDITIONAL TRANCHES Source text for Eikon: Further company coverage:

  10. Show article details.

    Corium Secures $235 Million in Debt Financing

    PR Newswire – 8:00 AM ET 09/27/2021

    BOSTON, Sept. 27, 2021  Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, today announces that it has closed on a $235 million term loan agreement with Hercules Capital, Inc. (HTGC), a leader in specialty financing for life science and technology companies. Corium will receive an initial tranche of $100 m...

  11. Show article details.

    Hercules Capital Delivers a New Record by Surpassing $1.5 Billion of Annual Gross Debt and Equity Commitments

    Business Wire – 6:00 AM ET 09/27/2021

    Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it, together with external funds managed by its adviser subsidiary, have originated more than $1.5 billion year-to-date in annual total gross deb...

  12. Show article details.

    BRIEF-Phathom Pharmaceuticals Secures $200 Million Term Loan Facility From Hercules Capital

    Reuters – 8:12 AM ET 09/20/2021

    Phathom Pharmaceuticals Inc (PHAT): * PHATHOM PHARMACEUTICALS SECURES $200 MILLION TERM LOAN FACILITY FROM HERCULES CAPITAL. * Phathom Pharmaceuticals Inc (PHAT) - NON-DILUTIVE FINANCING EXTENDS PHATHOM'S PROJECTED CASH RUNWAY TO MID-2023.

  13. Show article details.

    Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

    GlobeNewswire – 8:00 AM ET 09/20/2021

    Phathom Pharmaceuticals (PHAT), Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan facility from Hercules Capital, Inc. (HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets.

  14. Show article details.

    BRIEF-Hercules Capital Closes Public Offering Of $325.0 Mln 2.625% Notes Due 2026

    Reuters – 4:10 PM ET 09/16/2021

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL CLOSES PUBLIC OFFERING OF $325.0 MILLION 2.625% NOTES DUE 2026 Source text for Eikon: Further company coverage:

  15. Show article details.

    Hercules Capital Closes Public Offering of $325.0 Million 2.625% Notes due 2026

    Business Wire – 4:10 PM ET 09/16/2021

    Notes due 2026 Initially Assigned a Baa3 and BBB+ by Moody’s Investors Service and Kroll Bond Rating Agency, Respectively Hercules Capital, Inc. (HTGC), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 2.625% notes due 2026.

  16. Show article details.

    BRIEF-Hercules Capital Prices Public Offering Of $325.0 Million 2.625% Notes Due 2026

    Reuters – 5:20 PM ET 09/13/2021

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL PRICES PUBLIC OFFERING OF $325.0 MILLION 2.625% NOTES DUE 2026 Source text for Eikon: Further company coverage:

  17. Show article details.

    Hercules Capital Prices Public Offering of $325.0 Million 2.625% Notes Due 2026

    Business Wire – 4:41 PM ET 09/13/2021

    Hercules Capital, Inc. (HTGC), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 2.625% notes due September 2026.

  18. Show article details.

    BRIEF-Hercules Capital Inc Files Prospectus Supplement Related To Offering Of Notes; Size Not Disclosed

    Reuters – 2:33 PM ET 09/13/2021

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF NOTES; SIZE NOT DISCLOSED - SEC FILING Source text - https://bit.ly/3z5FjXR Further company coverage:

  19. Show article details.

    BRIEF-Better Therapeutics Secures $50 Mln Debt Facility From Hercules Capital

    Reuters – 8:46 AM ET 08/25/2021

    Hercules Capital Inc (HTGC): * BETTER THERAPEUTICS SECURES $50 MILLION DEBT FACILITY FROM HERCULES CAPITAL Source text for Eikon: Further company coverage:

  20. Show article details.

    Better Therapeutics Secures $50 Million Debt Facility From Hercules Capital

    Business Wire – 8:00 AM ET 08/25/2021

    Provides up to $150 million in total financing in combination with proceeds from previously announced SPAC merger and PIPE investment Funds to support advancement of clinical pipeline and commercialization of first prescription digital therapeutic for treating type 2 diabetes SAN FRANCISCO---- Better Therapeutics, Inc., a prescription digital therapeutics company developing cognitive behavioral...

Page:

Today's and Upcoming Events

  • Oct
    28

    HTGC to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    10

    HTGC ex-Dividend for $0.32 on 08/10/2021

    • Announce Date: 07/27/2021
    • Record Date: 08/11/2021
    • Pay Date: 08/18/2021
  • Aug
    10

    HTGC ex-Dividend for $0.07 on 08/10/2021

    • Announce Date: 07/27/2021
    • Record Date: 08/11/2021
    • Pay Date: 08/18/2021
  • Jul
    29

    HTGC announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.